Infant formula counterfeits & terrorism
This article was originally published in The Tan Sheet
Executive Summary
FDA recently "became aware of infant formula that was tampered with that was used to fund al Quaeda operatives," FDA Associate Commissioner for Regulatory Affairs Steven Niedelman said at the Food & Drug Law Institute's Enforcement & Litigation Conference in Washington D.C. Sept. 23. "Terrorism has become a big issue for the agency and one that all firms need to take into account," he noted. House Energy & Commerce Committee Senior Counsel Alan Slobodin asserted two years ago that terrorist organizations often are financed through counterfeit trade of consumer products such as infant formula (1"The Tan Sheet" Oct. 8, 2001, In Brief)...
You may also be interested in...
FDA "National Security" Mission: Counterfeiting And Bioterrorism?
FDA should heighten its focus on product security to ensure counterfeiting does not take place, not only for consumer safety, but to cut off a source of income for terrorists, asserted House Energy & Commerce Committee Senior Counsel Alan Slobodin.
Setback For Athenex, Hanmi As CRL Requests New Trial
Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.
Chordia Looks To Forge Own Path In Oncology
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: